New Therapeutic Approved by FDA to Treat Breast Cancer
Earlier this week, the U.S. Food and Drug Administration approved the molecularly targeted therapeutic ribociclib (Kisqali) for use in...
SABCS 2021: Zooming in on Breast Cancer Response to Immunotherapy at the Single-cell Level
Triple-negative breast cancer (TNBC) is aggressive, with high risk of metastasis and recurrence, and is challenging to treat due to a lack of effective targeted therapies. However, a higher...
SABCS 2014: A Bullet Against Breast Cancer Women Aren’t Using
Guest Post by Anees B. Chagpar, MD, MPH, MBA Yale Cancer Center
SABCS 2021: How Are Breast Cancer Survivors Navigating Life During the COVID-19 Pandemic?
When Abigail Johnston’s first child entered preschool six years ago, a vigilant pediatrician recommended an unusual strategy for minimizing...
Learning How to Target “Untargetable” Breast Cancer Through Basic Cancer Research
Sara Hanna Velarde, PhD, began her career in cancer research as a graduate student at the University of North...
Experts Explore How to Treat Each Stage of Triple-negative Breast Cancer
Researchers and a patient advocate weighed in on current and emerging treatment options for each stage of triple-negative breast...
A Call for Nuance in Thinking About Breast Cancer
In a Los Angeles Times op-ed, Cynthia Ryan, a two-time breast cancer survivor, past participant in the AACR Scientist↔Survivor...
Experts Forecast Cancer Research and Treatment Advances in 2021
2020 was filled with unexpected challenges for cancer research and patient care. As many of us shifted our lives...
50 Years of Progress: AACR Journal Highlights Landmark Discoveries in Cancer Research
On December 23, 1971, when President Richard Nixon signed the National Cancer Act of 1971 into law, cancer was considered a death sentence. Only 42 percent of those diagnosed with cancer survived five years past diagnosis,...
From the Journals: Bras Do Not Increase Breast Cancer Risk
A recent study in the AACR’s journal Cancer Epidemiology, Biomarkers & Prevention confirms that there is no increased risk...
AACR Virtual Annual Meeting I: The Promises and Challenges of Expanding the Use of Immune Checkpoint Inhibitors Through Combination Therapy
The cutting-edge scientific program for the AACR Virtual Annual Meeting I began Monday, April 27, with an Opening Clinical Plenary featuring...
From the Journals: Some Oral Contraceptives May Increase the Risk for Breast Cancer
Women who take high-dose estrogen birth control pills may be increasing their risk for breast cancer, according to a...
AACR Journals Share Selected Articles for March
As we welcome spring, enjoy the latest round of editors’ picks selected by the editors of AACR’s 10 journals....
Editors’ Picks, December 2024: Immunosuppression in the Lung, New Mathematical Models, and More
This month, the editors of the AACR journals highlighted studies about the gut microbiome in lung cancer, modeling the...
January Editors’ Picks from AACR Journals
The new year has already ushered in some changes, but one thing stays the same. Each month, we’ll continue to feature the “must read” articles handpicked by the editors...
Editors’ Picks, July 2025: U.S. Cancer Mortality Hotspots, Chemotherapy-induced Hearing Loss, and More
This month, the AACR's journals editors highlighted studies on U.S. cancer mortality hotspots, chemotherapy-induced hearing loss, and more.
Examining the Rise of Early-onset Incidence Across Cancer Types
Researchers are exploring which cancer types have higher incidence in people under 50, what may be causing this rise...
SABCS 2015: Symposium Co-director Carlos L. Arteaga Previews Important Advances to be Presented
Studies presented at this year’s San Antonio Breast Cancer Symposium shed light on new investigational therapies for patients with...
AACR Journal Editors Share Selected Articles
As February gives way to March, we bring you the latest round of editors’ picks selected by the editors...
Editors’ Picks, March 2025: Cancer Cell Senescence, Ultraviolet Protection, and More
This month, the editors of AACR's journals tout studies showcasing the immunostimulatory impact of senescent cancer cells, a novel...
Editors’ Picks, March 2024: Synergy’s Impact on Resistance, New Early Detection Tools, and More
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
Editors’ Picks: May Highlights from the AACR Journals
Another month brings another round of Editors’ Picks! As we picked our May flowers, the editors picked their favorite...
SABCS 2023: Some Patients May Safely Skip Radiation
Studies featured at this year’s San Antonio Breast Cancer Symposium (SABCS) suggest that—in some situations—adjuvant radiotherapy may not be...
Editors’ Picks: February 2024 Highlights from AACR Journals
February’s selections include a modified Zika virus to treat cancer, insights into treatment resistance, and more.
Editors Share Highlights from AACR Journals
As we begin a new month, it is time to look back at some of the exciting research published in the nine AACR journals last month. For the...
Cancer Treatment: Can Less Be More?
Molecular profiling of individual cancers can determine who needs what treatment, and who can avoid certain treatments and complications....
The Five ‘W’s’ (and ‘H’) of SABCS 2023
Each December, an impressive cohort of breast cancer researchers gathers for the San Antonio Breast Cancer Symposium (SABCS), one...
Editors’ Picks, April 2025: Brain Cancer Evolution, New Treatment Approaches, and More
For April 2025, the editors of AACR's 10 journals highlighted studies on evolution in glioblastoma, new cancer treatment approaches,...
Editors’ Picks, March 2026: Pediatric Leukemia Development, Low-dose Tamoxifen Use, and More
In March, AACR's journals editors highlighted studies on the development of pediatric leukemia, the use of low-dose tamoxifen, and...
Risk or Relief? Menopausal Hormone Therapy for Women With BRCA Mutations
Amid the debate over menopausal hormone therapy and cancer risk, researchers at SABCS provided some clarity for women with...